About GNA Biosolutions
GNA Biosolutions is a company based in Planegg (Germany) founded in 2010 by Federico Francisco Bürsgens and Joachim Anton Stehr.. GNA Biosolutions has raised $20.2 million across 3 funding rounds from investors including European Union, KfW and Mey Capital Matrix. The company has 29 employees as of December 31, 2020. GNA Biosolutions operates in a competitive market with competitors including Nanopore, PacBio, Omniome, Complete Genomics and OpGen, among others.
- Headquarter Planegg, Germany
- Employees 29 as on 31 Dec, 2020
- Founders Federico Francisco Bürsgens, Joachim Anton Stehr
-
Sectors
HealthcareTechnology
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$20.2 M (USD)
in 3 rounds
-
Latest Funding Round
$13.5 M (USD), Series C
Aug 05, 2019
-
Investors
European Union
& 9 more
-
Employee Count
29
as on Dec 31, 2020
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of GNA Biosolutions
GNA Biosolutions has successfully raised a total of $20.2M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $13.5 million completed in August 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series C — $13.5M
-
First Round
First Round
(19 Jun 2015)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2019 | Amount | Series C - GNA Biosolutions | Valuation | OCCIDENT – The Science Investor. , GreyBird Ventures | |
| Dec, 2017 | Amount | Grant - GNA Biosolutions | Valuation |
investors |
|
| Jun, 2015 | Amount | Series B - GNA Biosolutions | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in GNA Biosolutions
GNA Biosolutions has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union, KfW and Mey Capital Matrix. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Healthcare-focused private equity investments are managed by SHS Capital.
|
Founded Year | Domain | Location | |
|
Investments are directed toward enterprise software, mobility, and industrial technologies.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by GNA Biosolutions
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - GNA Biosolutions
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Gna Biosolutions Comparisons
Competitors of GNA Biosolutions
GNA Biosolutions operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nanopore, PacBio, Omniome, Complete Genomics and OpGen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Nanopore-based electronic systems for single-molecule analysis are developed.
|
|
| domain | founded_year | HQ Location |
Instrument systems and software for single-molecule real-time sequencing are developed.
|
|
| domain | founded_year | HQ Location |
Genome sequencing platform is provided for clinical diagnostics.
|
|
| domain | founded_year | HQ Location |
DNA sequencing platform for human genome analysis is developed.
|
|
| domain | founded_year | HQ Location |
Developer of diagnostics and bioinformatics platforms for providers
|
|
| domain | founded_year | HQ Location |
Provider of DNA sequencing technologies for applied genomic testing and medical sequencing
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Gna Biosolutions
Frequently Asked Questions about GNA Biosolutions
When was GNA Biosolutions founded?
GNA Biosolutions was founded in 2010 and raised its 1st funding round 5 years after it was founded.
Where is GNA Biosolutions located?
GNA Biosolutions is headquartered in Planegg, Germany. It is registered at Planegg, Bavaria, Germany.
Who is the current CEO of GNA Biosolutions?
Federico Francisco Bürsgens is the current CEO of GNA Biosolutions. They have also founded this company.
Is GNA Biosolutions a funded company?
GNA Biosolutions is a funded company, having raised a total of $20.2M across 3 funding rounds to date. The company's 1st funding round was a Series B of $6.7M, raised on Jun 19, 2015.
How many employees does GNA Biosolutions have?
As of Dec 31, 2020, the latest employee count at GNA Biosolutions is 29.
What does GNA Biosolutions do?
Founded in 2010 and based in Planegg, Germany, instruments, OEM modules, and assays for molecular pathogen detection are developed by the company. A novel PCR approach with enhanced cooling and heating rates is utilized to support bacterial disease diagnosis in clinical settings. The initial product, Pharos400, incorporates laser-based PCR for thermal cycling and real-time result readout without fluorescence. Operations focus on the biotechnology sector serving physicians and hospitals.
Who are the top competitors of GNA Biosolutions?
Who are GNA Biosolutions's investors?
GNA Biosolutions has 10 investors. Key investors include European Union, KfW, Mey Capital Matrix, SHS Capital, and UVC Partners.